Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the...

Biotech,rare diseases,pharmaceuticals,drug development,life sciences,and healthcare

Eloxx pharmaceuticals operates in the Biotechnology research industry.

Eloxx pharmaceuticals's revenue is 11m - 100m

Eloxx pharmaceuticals has 11 - 50 employees.